In an interview on CNBC's Mad Money, Ynon Kreiz said Mattel had a strong upswing in revenue and profitability in Q3 with gross margin at 51%. "Our brands and product offerings resonate with consumers and parents continue to spend on their children," Kreiz noted. He said Barbie is doing amazingly well with demand up 50%. "We are seeing a strong demand for our products and there is a lot of momentum heading into the holiday season," Kreiz added.

This is the 4th consecutive decrease and the lowest level of holdings since September 18th.

Point72 Asset Management disclosed a 7.9% stake in Bellus Health, which represents over 6.2M shares. The filing does not allow for activism.

In a regulatory filing, Kraft Heinz said that, on October 23, 2020, chief growth officer Nina Barton decided to leave the company to pursue other career opportunities. Barton has agreed to continue her employment with the company until May 31, 2021 in a new role as Strategic Advisor effective November 30, 2020.

Galera Therapeutics announced the release of the abstract containing interim data from the first 19 patients in its pilot Phase 1/2 clinical trial designed to evaluate the safety and efficacy of avasopasem manganese in combination with stereotactic body radiation therapy, compared with SBRT and placebo, in patients with locally advanced pancreatic cancer. The interim data were shared in abstract #LBA5 on the 2020 American Society for Radiation Oncology Annual Meeting virtual program website. Galera's investigational, highly selective small molecule superoxide dismutase (SOD) mimetics are designed to rapidly and selectively convert superoxide to hydrogen peroxide and oxygen. These dismutase mimetics have potential anti-cancer synergy based on positive results in multiple preclinical models. In the initial analysis of the intent-to-treat cohort enrolled in the first, single-center stage of the trial, which comprises all patients followed for over a year, median overall survival had not yet been reached in the GC4419 arm, compared to 40.4 weeks in the placebo arm. The GC4419 arm also demonstrated favorable progression-free survival, locoregional control and time-to-distant metastases compared to the placebo arm. The incidence of acute or late Grade 3+ toxicity post-SBRT was similar in both arms.

SolarWinds announced it has signed a definitive agreement to acquire SentryOne, a technology provider of database performance monitoring and DataOps solutions on SQL Server, Azure SQL Database, and the Microsoft Data Platform. The expected addition of the SentryOne products to the SolarWinds portfolio also will amplify the depth and breadth of support SolarWinds can offer for Microsoft and Microsoft Azure environments. The transaction is expected to close later this month.